BACKGROUND:Patients with high blood pressure (BP) visit a physician an average of 4 times or more per year in the U.S., yet BP is controlled in fewer than half. Practical, robust and sustainable models are needed to improve BP in patients with uncontrolled hypertension. OBJECTIVES: The Home Blood Pressure Telemonitoring and Case Management to Control Hypertension study (HyperLink) is a cluster-randomized trial designed to determine whether an intervention that combines home BP telemonitoring with pharmacist case management improves BP control compared to usual care at 6 and 12 months in patients with uncontrolled hypertension. Secondary outcomes are maintenance of BP control at 18 months, patient satisfaction with their health care, and costs of care. METHODS:HyperLink enrolled 450 hypertensive patients with uncontrolled BP from 16 primary care clinics. Eight clinics were randomized to provide usual care (UC) to their patients (n=222) and 8 were randomized to provide the telemonitoring intervention (TI) (n=228). TI patients received home BP telemonitors that internally store and electronically transmit BP data to a secure database. Pharmacist case managers adjust antihypertensive therapy based on the home BP data under a collaborative practice agreement with the clinics' primary care teams. The length of the intervention is 12 months, with follow-up to 18 months to determine the durability of the intervention. CONCLUSIONS: We will test in a real primary care setting whether combining BP telemonitoring and pharmacist case management can achieve and maintain high rates of BP control compared to usual care.
RCT Entities:
BACKGROUND:Patients with high blood pressure (BP) visit a physician an average of 4 times or more per year in the U.S., yet BP is controlled in fewer than half. Practical, robust and sustainable models are needed to improve BP in patients with uncontrolled hypertension. OBJECTIVES: The Home Blood Pressure Telemonitoring and Case Management to Control Hypertension study (HyperLink) is a cluster-randomized trial designed to determine whether an intervention that combines home BP telemonitoring with pharmacist case management improves BP control compared to usual care at 6 and 12 months in patients with uncontrolled hypertension. Secondary outcomes are maintenance of BP control at 18 months, patient satisfaction with their health care, and costs of care. METHODS: HyperLink enrolled 450 hypertensivepatients with uncontrolled BP from 16 primary care clinics. Eight clinics were randomized to provide usual care (UC) to their patients (n=222) and 8 were randomized to provide the telemonitoring intervention (TI) (n=228). TI patients received home BP telemonitors that internally store and electronically transmit BP data to a secure database. Pharmacist case managers adjust antihypertensive therapy based on the home BP data under a collaborative practice agreement with the clinics' primary care teams. The length of the intervention is 12 months, with follow-up to 18 months to determine the durability of the intervention. CONCLUSIONS: We will test in a real primary care setting whether combining BP telemonitoring and pharmacist case management can achieve and maintain high rates of BP control compared to usual care.
Authors: Hayden B Bosworth; Benjamin J Powers; Maren K Olsen; Felicia McCant; Janet Grubber; Valerie Smith; Pamela W Gentry; Cynthia Rose; Courtney Van Houtven; Virginia Wang; Mary K Goldstein; Eugene Z Oddone Journal: Arch Intern Med Date: 2011-07-11
Authors: Russell E Glasgow; Edward H Wagner; Judith Schaefer; Lisa D Mahoney; Robert J Reid; Sarah M Greene Journal: Med Care Date: 2005-05 Impact factor: 2.983
Authors: Richard J McManus; Jonathan Mant; Emma P Bray; Roger Holder; Miren I Jones; Sheila Greenfield; Billingsley Kaambwa; Miriam Banting; Stirling Bryan; Paul Little; Bryan Williams; F D Richard Hobbs Journal: Lancet Date: 2010-07-08 Impact factor: 79.321
Authors: Susan A Oliveria; Pablo Lapuerta; Bruce D McCarthy; Gilbert J L'Italien; Dan R Berlowitz; Steven M Asch Journal: Arch Intern Med Date: 2002-02-25
Authors: Heather M Johnson; Lisa Sullivan-Vedder; KyungMann Kim; Patrick E McBride; Maureen A Smith; Jamie N LaMantia; Jennifer T Fink; Megan R Knutson Sinaise; Laura M Zeller; Diane R Lauver Journal: Contemp Clin Trials Date: 2019-01-21 Impact factor: 2.226
Authors: Karen L Margolis; Stephen E Asche; Anna R Bergdall; Steven P Dehmer; Sarah E Groen; Holly M Kadrmas; Tessa J Kerby; Krissa J Klotzle; Michael V Maciosek; Ryan D Michels; Patrick J O'Connor; Rachel A Pritchard; Jaime L Sekenski; JoAnn M Sperl-Hillen; Nicole K Trower Journal: JAMA Date: 2013-07-03 Impact factor: 56.272
Authors: Stephen E Asche; Patrick J O'Connor; Steven P Dehmer; Beverly B Green; Anna R Bergdall; Michael V Maciosek; Rachel A Nyboer; Pamala A Pawloski; JoAnn M Sperl-Hillen; Nicole K Trower; Karen L Margolis Journal: J Am Soc Hypertens Date: 2016-09-25
Authors: Karen L Margolis; Stephen E Asche; Anna R Bergdall; Steven P Dehmer; Michael V Maciosek; Rachel A Nyboer; Patrick J O'Connor; Pamala A Pawloski; JoAnn M Sperl-Hillen; Nicole K Trower; Ann D Tucker; Beverly B Green Journal: J Gen Intern Med Date: 2015-11 Impact factor: 5.128
Authors: Tessa J Kerby; Stephen E Asche; Michael V Maciosek; Patrick J O'Connor; Joann M Sperl-Hillen; Karen L Margolis Journal: J Clin Hypertens (Greenwich) Date: 2012-07-26 Impact factor: 3.738
Authors: Karen L Margolis; Steven P Dehmer; JoAnn Sperl-Hillen; Patrick J O'Connor; Stephen E Asche; Anna R Bergdall; Beverly B Green; Rachel A Nyboer; Pamala A Pawloski; Nicole K Trower; Michael V Maciosek Journal: Hypertension Date: 2020-08-31 Impact factor: 10.190
Authors: P A Pawloski; S E Asche; N K Trower; A R Bergdall; S P Dehmer; M V Maciosek; R A Nyboer; P J O'Connor; J M Sperl-Hillen; B B Green; K L Margolis Journal: J Clin Pharm Ther Date: 2016-06-30 Impact factor: 2.512
Authors: Steven P Dehmer; Michael V Maciosek; Nicole K Trower; Stephen E Asche; Anna R Bergdall; Rachel A Nyboer; Patrick J O'Connor; Pamela A Pawloski; JoAnn M Sperl-Hillen; Beverly B Green; Karen L Margolis Journal: J Am Coll Clin Pharm Date: 2018-04-14